ALLO-316 Demonstrates Antitumor Activity in Advanced Clear Cell RCC
The allogeneic anti-CD70 CAR T-cell therapy ALLO-316 elicited signals of antitumor activity and showed a tolerable safety profile in patients with advanced or metastatic clear cell renal cell carcinoma.
United States Noord Holland University Medical Center Samera Srour John Haanen Netherlands Cancer Institute
Source: onclive.com